Literature DB >> 7541725

Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells.

M Fridkis-Hareli1, D Teitelbaum, R Arnon, M Sela.   

Abstract

In the present study we attempted to examine whether copolymer 1 (Cop 1), a synthetic basic random copolymer of amino acids (a candidate drug for multiple sclerosis (MS)), and myelin basic protein (MBP) undergo processing prior to their binding to MHC class II molecules on antigen-presenting cells (APC). The direct binding of biotinylated Cop 1 and MBP to living APC was monitored by flow cytometry using phycoerythrin (PE)-streptavidin. The time course for either Cop 1 or MBP binding was similar at 37 degrees C and on ice. Both Cop 1 and MBP bound to glutaraldehyde-fixed APC. Furthermore, these biotinylated antigens bound also in the presence of protease inhibitors and lysosomotropic agents, suggesting that proteolysis is not required prior to their interaction with the MHC determinants. Finally, short fragments of Cop 1 molecule did not bind to most of the APC, suggesting that the polymeric nature of Cop 1 is important for its efficient and promiscuous binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541725     DOI: 10.1006/cimm.1995.1121

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice.

Authors:  Kazuyuki Kawamura; Katherine A McLaughlin; Robert Weissert; Thomas G Forsthuber
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

Review 2.  New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  R Arnon; M Sela; D Teitelbaum
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

Review 3.  Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

Authors:  Sara J Ireland; Nancy L Monson; Laurie S Davis
Journal:  Cytokine       Date:  2015-03-17       Impact factor: 3.861

4.  A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

Authors:  P G Schlegel; R Aharoni; Y Chen; J Chen; D Teitelbaum; R Arnon; M Sela; N J Chao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

5.  Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

Authors:  M Fridkis-Hareli; E F Rosloniec; L Fugger; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

6.  Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.

Authors:  Masha Fridkis-Hareli; Laura Santambrogio; Joel N H Stern; Lars Fugger; Celia Brosnan; Jack L Strominger
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 7.  Therapeutic vaccines in autoimmunity.

Authors:  Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-12       Impact factor: 11.205

Review 8.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.